Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients

Inclusion Criteria: * Patients ≥ 18 years old. * Fulfilling the 2010 American College of Rheumatology (ACR)/EULAR criteria for RA. * Treated with a stable dose of Synthetic Disease Modifying Anti-Rheumatic Drugs (sDMARD) or Biological Disease Modifying Anti-Rheumatic Drug (bDMARD) for at least 3 months. * Who have been treated with prednisone or prednisolone for at least 6 months. * With a stable dose of prednisone or prednisolone of 5mg/day for at least 3 months. * With a DAS28 ≤3.2 for at least 3 months. * Patients with health insurance * Patients who have signed a written informed consent form. Exclusion Criteria: * Any chronic condition that would need long term corticoid use (e.g. chronic lung diseases). * Evidence of a flare within the last 3 months. * Evidence of an allergy or intolerance to hydrocortisone or prednisone. * Chronic idiopathic, or autoimmune clinical adrenal insufficiency. * GC joint injections within the last 3 months or scheduled in the next 3 months. * Any GC intake expected more than \>5mg/day within the next 12 months. * Association with sultopride and with live vaccines * Significant trauma or major surgery within the 3 months prior to the baseline visit. * Scheduled surgery in the next 12 months. * Fibromyalgia. * Foreseeable poor compliance with the strategy. * Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation. * Alcohol and/or drug misuse as determined by the investigator. * Pregnancy or breastfeeding. * Patient is not willing to sign the informed consent. * Juridical Protection * DAS28\>3.2 after one month of a stable dose of prednisone 5 mg/day.